# A Randomized, Open-Label, Multi-Center Study To Evaluate The Efficacy And Safety Of Intramuscular Ziprasidone In Patients With Agitation

> **NCT00723606** · PHASE3 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 376 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Intramuscular ziprasidone mesylate
- **DRUG:** Intramuscular haloperidol

## Key facts

- **NCT ID:** NCT00723606
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 376 (ACTUAL)
- **Last updated:** 2021-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00723606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00723606, "A Randomized, Open-Label, Multi-Center Study To Evaluate The Efficacy And Safety Of Intramuscular Ziprasidone In Patients With Agitation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00723606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*